[go: up one dir, main page]

WO2003068935A3 - Methods of therapy and diagnosis - Google Patents

Methods of therapy and diagnosis Download PDF

Info

Publication number
WO2003068935A3
WO2003068935A3 PCT/US2003/004515 US0304515W WO03068935A3 WO 2003068935 A3 WO2003068935 A3 WO 2003068935A3 US 0304515 W US0304515 W US 0304515W WO 03068935 A3 WO03068935 A3 WO 03068935A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell surface
cell
surface antigen
cells
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/004515
Other languages
French (fr)
Other versions
WO2003068935A2 (en
Inventor
Peter Emtage
Douglas A Dedera
Bryan J Boyle
Jian-Rui Wang
Huang-Tsu Chen
Ching-Yi Wan
Victoria Yamazaki
Vinod Asundi
Chenghua Liu
Y Tom Tang
Radoje T Drmanac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Nuvelo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/146,619 external-priority patent/US20030215453A1/en
Priority claimed from US10/218,325 external-priority patent/US7109030B2/en
Priority claimed from US10/302,444 external-priority patent/US20040022786A1/en
Priority claimed from US10/327,491 external-priority patent/US20040023870A1/en
Priority claimed from US10/327,413 external-priority patent/US7029677B2/en
Priority to EP03709107A priority Critical patent/EP1483407A4/en
Priority to CA002476555A priority patent/CA2476555A1/en
Priority to AU2003213064A priority patent/AU2003213064C1/en
Application filed by Nuvelo Inc filed Critical Nuvelo Inc
Publication of WO2003068935A2 publication Critical patent/WO2003068935A2/en
Publication of WO2003068935A3 publication Critical patent/WO2003068935A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Certain cells, including types of cancer cells such as B-cell lymphoma, T-cell lymphoma, T-cell leukemia, multiple myeloma, and Hodgkin's Disease, are capable of expressing cell surface antigen RNA and proteins. Targeting using cell surface antigen polypeptides, nucleic acids encoding for cell surface antigen polypeptides, antibodies specific for cell surface antigens, and small molecules and peptides that bind to or recognize said cell surface antigens, provides a method of killing or inhibiting that growth of cells that express the cell surface antigen protein. Methods of therapy and diagnosis of disorders associated with cell surface protein-expressing cells are described.
PCT/US2003/004515 2000-01-25 2003-02-14 Methods of therapy and diagnosis Ceased WO2003068935A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003213064A AU2003213064C1 (en) 2000-01-25 2003-02-14 Methods of therapy and diagnosis
CA002476555A CA2476555A1 (en) 2002-02-14 2003-02-14 Methods of therapy and diagnosis
EP03709107A EP1483407A4 (en) 2002-02-14 2003-02-14 THERAPY AND DIAGNOSTIC PROCEDURES

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US7767602A 2002-02-14 2002-02-14
US10/077,676 2002-02-14
US7808002A 2002-02-15 2002-02-15
US10/078,080 2002-02-15
US8713702A 2002-02-27 2002-02-27
US10/087,137 2002-02-27
US9298502A 2002-03-06 2002-03-06
US10/092,985 2002-03-06
US10/146,619 US20030215453A1 (en) 2002-05-14 2002-05-14 Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US10/146,619 2002-05-14
US10/218,325 2002-08-12
US10/218,325 US7109030B2 (en) 2000-03-31 2002-08-12 Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US10/302,444 US20040022786A1 (en) 2000-01-21 2002-11-22 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US10/302,444 2002-11-22
US10/327,491 US20040023870A1 (en) 2000-01-21 2002-12-19 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US10/327,413 US7029677B2 (en) 2000-01-25 2002-12-19 Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
US10/327,413 2002-12-19
US10/327,491 2002-12-19

Publications (2)

Publication Number Publication Date
WO2003068935A2 WO2003068935A2 (en) 2003-08-21
WO2003068935A3 true WO2003068935A3 (en) 2004-06-10

Family

ID=27739558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004515 Ceased WO2003068935A2 (en) 2000-01-25 2003-02-14 Methods of therapy and diagnosis

Country Status (3)

Country Link
EP (1) EP1483407A4 (en)
CA (1) CA2476555A1 (en)
WO (1) WO2003068935A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107118D0 (en) 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
EP2934585B1 (en) 2012-12-21 2018-06-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
WO2021097538A1 (en) * 2019-11-22 2021-05-27 The University Of Sydney Bone formation
CN113138281B (en) * 2021-04-28 2024-07-30 首都医科大学附属北京友谊医院 Detection device and electronic equipment for primary hemophagocytic syndrome
WO2024196877A1 (en) * 2023-03-22 2024-09-26 University Of Florida Research Foundation, Incorporated Rabbit monoclonal antibodies targeting acute myeloid leukemia antigens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
AU2001231178A1 (en) * 2000-01-25 2001-08-07 Nuvelo, Inc. Methods and materials relating to CD84-like polypeptides and polynucleotides
AU2001253362A1 (en) * 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
EP1223218A1 (en) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 1 December 2001 (2001-12-01), BOTTINO ET AL.: "Activating NK receptor precursor", XP002975092, Database accession no. Q96DV0 *
DATABASE GENBANK [online] 1 October 2001 (2001-10-01), KUO ET AL.: "Amino acid sequence of a CD84-like polypeptide", XP002191988, Database accession no. AAG63166 *
DATABASE GENBANK [online] 23 August 2001 (2001-08-23), BOTTINO ET AL.: "Homo sapiens mRNA for activation NK receptor (KALI gent)", XP002975091, Database accession no. HSA27741 *
DATABASE GENBANK [online] 23 August 2001 (2001-08-23), BOTTINO ET AL.: "Homo sapiens mRNA for NTB-A receptor (KALI b gene)", XP002975090, Database accession no. HSA306388 *
See also references of EP1483407A4 *

Also Published As

Publication number Publication date
EP1483407A4 (en) 2006-11-15
EP1483407A2 (en) 2004-12-08
CA2476555A1 (en) 2003-08-21
WO2003068935A2 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
WO2002000692A3 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
AU2001258567A1 (en) Humanised antibodies to the epidermal growth factor receptor
WO1998050547A3 (en) Human toll-like receptor proteins, related reagents and methods
WO2006126069A3 (en) A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
EP0757099A3 (en) CTLA4 mutant molecules and uses thereof
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
CY1109715T1 (en) IL-1b Binding Antibodies and their Fragments
EP1158004A3 (en) Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
WO2005051999A3 (en) Substance binding human igg fc receptor iib
WO2006068975A3 (en) Binding proteins specific for human matriptase
WO2003068935A3 (en) Methods of therapy and diagnosis
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
WO2001091739A3 (en) Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
WO2002097041A3 (en) Fusion proteins of biologically active peptides and antibodies
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
WO2004047758A3 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
WO2004053061A8 (en) Methods of therapy and diagnosis using targeting of cells that express lax
WO2005060375A3 (en) Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
WO2005058362A3 (en) Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003213064

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2476555

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003709107

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003709107

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP